| Lu, Qianjin |
NCT04875169: Evaluate Efficacy and Safety of Oral SHR0302 in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis |
|
|
| Completed | 3 | 336 | Canada, RoW | Core Treatment Active Experimental: SHR0302 Dose#1, Core Treatment Active Experimental: SHR0302 Dose#2, Core Treatment Placebo Comparator: Placebo, Extension Treatment Active Experimental: SHR0302 Dose#1, Extension Treatment Active Experimental: SHR0302 Dose#2 | Reistone Biopharma Company Limited | Atopic Dermatitis | 08/22 | 05/23 | | |
HSK16149-302, NCT05140863: To Evaluate the Efficacy and Safety of HSK16149 Capsule in Chinese Patients With Postherpetic Neuralgia |
|
|
| Completed | 3 | 372 | RoW | HSK16149 20mg BID, HSK16149 40mg BID, Placebo BID | Haisco Pharmaceutical Group Co., Ltd. | Postherpetic Neuralgia | 12/22 | 01/23 | | |
NCT05051761: Study to Evaluate the Safety and Efficacy of Jaktinib in Adults With Alopecia Areata |
|
|
| Active, not recruiting | 3 | 425 | RoW | Jaktinib, placebo | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Alopecia Areata | 12/24 | 12/24 | | |
NCT05676242: A Phase III Extended Clinical Trial of Jaktinib Hydrochloride Tablets in the Treatment of Moderate and Severe Atopic Dermatitis |
|
|
| Recruiting | 3 | 400 | RoW | Jaktinib Hydrochloride Tablet | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Atopic Dermatitis | 12/24 | 12/24 | | |
NCT05255237: Extension Study to Evaluate Safety and Efficacy of Jaktinib in Adults With Alopecia Areata |
|
|
| Active, not recruiting | 3 | 315 | RoW | Jaktinib | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Alopecia Areata | 06/25 | 12/25 | | |
NCT05526222: A Phase III Study of Jaktinib in Adults With Moderate and Severe Atopic Dermatitis |
|
|
| Recruiting | 3 | 438 | RoW | Jaktinib Hydrochloride Tablet | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Atopic Dermatitis | 06/25 | 09/25 | | |
NCT06396026: A Study of Efficacy and Safety of TLL-018 in CSU Participants |
|
|
| Recruiting | 3 | 436 | RoW | TLL-018 tablets, Placebo tablets | Hangzhou Highlightll Pharmaceutical Co., Ltd | Chronic Spontaneous Urticaria | 03/26 | 12/27 | | |
NCT06723080: Phase III Clinical Study of VC005 Tablets in Adult Patients with Moderate to Severe Atopic Dermatitis |
|
|
| Recruiting | 3 | 480 | RoW | VC005 low dose group, VC005 high dose group, VC005 Placebo group | Jiangsu vcare pharmaceutical technology co., LTD | Moderate to Severe Atopic Dermatitis | 08/27 | 08/27 | | |
NCT04539639: Clinical Study of Jaktinib in the Treatment of Patients With Moderate and Severe Atopic Dermatitis |
|
|
| Completed | 2 | 166 | RoW | Jaktinib, placebo | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Atopic Dermatitis | 05/22 | 05/22 | | |
NCT05492591: A Study Exploring Efficacy of Peginterferon in Patients With Herpes Zoster |
|
|
| Completed | 2 | 50 | RoW | Peginterferon α1b, Peginterferon α1b with valacyclovir, Valacyclovir | Shanghai Institute Of Biological Products, Chinese Academy of Medical Sciences Dermatology Hospital | Herpes Zoster | 07/23 | 07/23 | | |
NCT06109818: Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis |
|
|
| Recruiting | 2 | 129 | RoW | ICP-488 Tablets, ICP-488 Placebo | Beijing InnoCare Pharma Tech Co., Ltd. | Moderate to Severe Plaque Psoriasis | 10/24 | 11/24 | | |
| Completed | 2 | 456 | Europe, Japan, US, RoW | Enpatoran low dose, M5049, Enpatoran medium dose, Enpatoran high dose, Placebo | EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany | Systemic Lupus Erythematosus | 11/24 | 11/24 | | |
|
|
NCT05997927: Efficacy and Safety Clinical Study of VC005 Tablets in Adult Patients With Moderate to Severe Atopic Dermatitis |
|
|
| Completed | 2 | 149 | RoW | VC005 tablets, VC005 Tablets Placebo | Jiangsu vcare pharmaceutical technology co., LTD | Moderate to Severe Atopic Dermatitis | 07/24 | 07/24 | | |
NCT04445363: A Study With Jaktinib Hydrochloride Cream Applied Topically to Subjects With Alopecia Areata |
|
|
| Active, not recruiting | 1/2 | 160 | RoW | Jaktinib hydrochloride cream, Jaktinib, Placebo | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Alopecia Areata(AA) | 12/24 | 12/24 | | |
NCT04435392: Jaktinib Hydrochloride Cream For Atopic Dermatitis |
|
|
| Completed | 1/2 | 107 | RoW | Jaktinib Hydrochloride Cream, Jaktinib, Placebo | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Atopic Dermatitis | 09/22 | 09/22 | | |
LK004102, NCT06553287: Safety, Tolerability and Pharmacokinetics of LNK01004 Ointment in Adults With Atopic Dermatitis. |
|
|
| Completed | 1 | 28 | RoW | LNK01004 ointment 0.3%, LNK01004 ointment 1.0%, LNK01004 ointment 1.5%, Vehicle BID | Lynk Pharmaceuticals Co., Ltd | Atopic Dermatitis | 06/24 | 06/24 | | |
NCT05451199: A Clinical Study of ICP-488 in Healthy Subjects and Patients With Psoriasis |
|
|
| Recruiting | 1 | 154 | RoW | ICP-488, Placebo | Beijing InnoCare Pharma Tech Co., Ltd. | Psoriasis | 10/23 | 12/23 | | |
NCT06009094: Safety, Tolerance and Pharmacokinetics Clinical Study of VC005 in Healthy Subjects and Patients with Mild to Moderate Atopic Dermatitis |
|
|
| Completed | 1 | 80 | RoW | VC005, VC005 Placebo | Jiangsu vcare pharmaceutical technology co., LTD | Atopic Dermatitis | 05/24 | 05/24 | | |
| Peng, Hong |
NCT04683406: A Study of ZSP1273 Tablets in Patients With Acute Uncomplicated Influenza A |
|
|
| Completed | 3 | 750 | RoW | ZSP1273 600 mg, Placebo to Oseltamivir, Oseltamivir(oral), Placebo to ZSP1273 | Guangdong Raynovent Biotech Co., Ltd | Influenza A | 04/23 | 05/23 | | |
| Terminated | 3 | 372 | Europe, US, RoW | Pamrevlumab, FG-3019, Placebo | FibroGen | Idiopathic Pulmonary Fibrosis | 09/23 | 09/23 | | |
|
TQA3605-II-01, NCT06644417: Clinical Study of TQA3605 Tablets Combined With Nucleoside (Acid) Analogs (NAs) Drugs Compared With NAs Drugs in the Treatment of Chronic Hepatitis B Virus (HBV) Infection |
|
|
| Recruiting | 2 | 120 | RoW | TQA3605 tablets plus NAs, TQA3605 Placebo plus NAs | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | HBV Infection With LLV | 04/26 | 08/26 | | |
